Back to Results
First PageMeta Content
Biology / Medicine / Pyrazines / Telaprevir / Cytokines / Hepatitis / Hepatitis C virus / Interferon / Hepatitis C / Antivirals / Pharmacology / Protease inhibitors


September 19, 2014 Press Release Mitsubishi Tanabe Pharma Corporation TELAVIC 250 mg Tablets, Antiviral Approval of Additional indication for Chronic Hepatitis C Genotype 2
Add to Reading List

Document Date: 2014-09-19 05:20:51

Open Document

File Size: 18,19 KB

Share Result on Facebook

City

Osaka / /

Company

Press Release Mitsubishi Tanabe Pharma Corporation / Mitsubishi Tanabe Pharma Corporation / /

Country

Japan / /

Event

FDA Phase / /

MedicalCondition

HCV genotype 1 / HCV genotype 2 / chronic hepatitis C / hepatitis C / HCV / /

Person

Masayuki Mitsuka / /

/

Position

Director / CEO / President & Representative / /

Product

ribavirin / TELAVIC® / /

Technology

Genotype / /

SocialTag